Skip to main content
SpringerLink
Log in

The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Over the past two decades there has been increasing interest in including patients’ self-reports in the management of their illness. Among the many reasons for such recent interest has been a rising consumer movement over the past few decades, which has led patients, their caregivers and their families to press for more meaningful sharing with physicians in the clinical decision-making process, with the clear expectations of better therapies and improved outcomes. Patients as consumers of services, their views, attitudes towards healthcare, as well as their level of satisfaction with care, have become increasingly recognized. The recent interest by the US Food and Drug Administration (FDA), as well as other regulatory agencies, in patient-reported outcomes (PROs) in the process of developing and testing new antipsychotics, has also added more impetus. It is clear that including patients in the decision-making process about the management of their psychiatric conditions also broadens the concept of ‘recovery’, by empowering patients to be active participants and gives a clear message that successful treatment in schizophrenia is more than a symptomatic improvement, but also includes improved functional status. Additionally, the recent interest in personalized medicine puts the patient in the centre of such development. Since 2004, when we published our review about the impact of new antipsychotics on quality of life in CNS Drugs, a number of newer antipsychotics have been introduced and include ziprasidone, aripiprazole, paliperidone, asenapine, iloperidone and lurasidone. The current review is based on 31 selected publications that cover the years 2004–2012, and deals with the impact of such newer antipsychotics on specific domains of PROs, such as subjective tolerability, quality of life, medication preference, satisfaction and social functioning. Most of the available data deal with ziprasidone, aripiprazole and paliperidone. Though the great majority of the studies indicate the newer antipsychotics have favourably impacted on aspects of PROs, such a conclusion can only be considered a trend due to the many design and methodological limitations of many of these studies. It is interesting to note, as the field awaits more rigorous studies, that there seems to be a unifying core that exists among the various subjective outcomes and that tends to generalize from one subjective outcome to other subjective outcomes. The patient who experiences good subjective tolerability to medications tends generally to be more satisfied and has a strong medication preference. The identification of such a unifying core can prove helpful, not only in the development of appropriate scales, but also in informing and guiding the process of development of new antipsychotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. U.S. Food and Drug Administration Guidance for Industry. Patient-Reported Outcome Measures; use in medical product development to support labelling claims, FDA (2006).

  2. Voruganti LNP, Heselgrave RS, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the question of subjectivity with the question of reliability. Psychol Med. 1998;28:165–72.

    Article  PubMed  CAS  Google Scholar 

  3. Awad AG, Voruganti LNP. The subjective/objective dichotomy: relevance to nosology, research and management. In: Gaebel W, editor. Zukunftsperspekiven in psychiatries und psychothezapie. Dormstadt: Stienkopff Verlog; 2002. p. 21–7.

    Chapter  Google Scholar 

  4. Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient related quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178–86.

    Article  PubMed  Google Scholar 

  5. Awad AG, Voruganti LNP. Intervention research in psychosis: issues related to assessment of quality of life. Schizophr Bull. 2000;26:557–64.

    Article  PubMed  CAS  Google Scholar 

  6. Voruganti LNP, Slomka P, Zabel P, et al. Subjective effect of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D2 binding ratios in SPECT imaging. Neuropsychopharmacology. 2001;25:642–50.

    Article  PubMed  CAS  Google Scholar 

  7. De Haan L, Lavalaye J, Linszend D, et al. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019–20.

    Article  PubMed  Google Scholar 

  8. Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia: findings from in vivo SPECT study. Schizophr Res. 2006;88:179–86.

    Article  PubMed  Google Scholar 

  9. Mizrahi R, Mamo D, Pausion P, et al. The relationship between subjective well-being and dopamine D2 receptors in patients treated with dopamine partial agonist and a full antagonist antipsychotic. Int J Neuropsychopharmacol. 2009;5:715–21.

    Article  Google Scholar 

  10. Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: What are they and are they being achieved? CNS Drugs. 1995;4:8–16.

    Article  Google Scholar 

  11. Ritsner M, Kurs R. Impact of antipsychotic agents and their side-effects on the quality of life in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2002;2:89–98.

    Article  Google Scholar 

  12. Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877–93.

    Article  PubMed  CAS  Google Scholar 

  13. Zacher JL, Holmes JC. Second-generation antipsychotics: a review of recently approved agents and drugs in the pipeline. Formulary. 2012;47:106–12

    Google Scholar 

  14. Tuanainen A, Wahlbeck K. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000; (2): CD000966.

  15. Citrome L. Iloperidone, asenapine and lurasidone: a brief overview of three new second-generation antipsychotics. Postgrad Med. 2011;123:153–62.

    Article  PubMed  Google Scholar 

  16. Edwards SJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparisons of randomized controlled trials. Clin Ther. 2009;31:1345–59.

    Article  PubMed  CAS  Google Scholar 

  17. Agency for Health Care Research and Quality (AHRQ). First generation versus second generation antipsychotics in adults: Comparative effectiveness. Executive Summary, Publication No. 12—EHC054-EF, 2012. http://www.effectivehealthcare.ahrg.gov/reports/final.cfm.

  18. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia—an update. Pharmacoeconomics. 2012;30:183–95.

    Article  PubMed  Google Scholar 

  19. Awad AG, Voruganti LNP, Heselgrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. 1997;6:21–6.

    Article  PubMed  CAS  Google Scholar 

  20. Mencaccic on behalf of all investigators. Efficacy and tolerability of switching to ziprasidone in Italian patients with acute exacerbation of schizophrenia—an open-label study. Pharmacopsychiatry. 2012;45:236–40.

    Article  Google Scholar 

  21. Huang M-W, Yang T-T, Ten P-R, et al. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol. 2012;12:1–11.

    Article  PubMed  CAS  Google Scholar 

  22. Grootens KP, van Vellen NM, Peuskens J, et al. Ziprasidone versus olanzapine in recent-onset schizophrenia and schizoaffective disorder—double-blind randomized controlled trial. Schizophr Bull. 2011;37:352–61.

    Article  PubMed  CAS  Google Scholar 

  23. Jui-Kang T, Wen-Kuo L, For-Wey L. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343–51.

    Article  Google Scholar 

  24. Liu-Seifert H, Osuntokun O, Godfrey J, et al. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369–77.

    PubMed  Google Scholar 

  25. Docherty JP, Baker RA, Eudicone J, et al. Effect of aripiprazole versus haloperidone on PANSS Prosocial items in early episode patients with schizophrenia. Schizophr Res. 2010;120:199–203.

    Article  PubMed  CAS  Google Scholar 

  26. Ming-Hong H, Wei-Wen L, Shao-Tsu C, et al. A 64-week multicentre, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann Gen Psychiatry. 2010;9:35. doi:10.1186/1744-859X-9-35.

    Article  Google Scholar 

  27. Shoemaker J, Naber D, Vrifland P, et al. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138–46.

    Article  Google Scholar 

  28. Stahl SM, Malla A, Newcomer JW, et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Clin Psychopharmacol. 2010;30:425–50.

    Article  CAS  Google Scholar 

  29. Canuso C, Grinspan A, Kalali A, et al. Medication satisfaction in schizophrenia: a blinded initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010;25:155–64.

    Article  PubMed  Google Scholar 

  30. Burns P, Morasini P, Gagnon DD, et al. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of pooled analysis of three phase III trials of paliperidone extended release tablets. Clin Ther. 2010;32:275–92.

    Article  PubMed  Google Scholar 

  31. de Oliveira IR, Elkis H, Gattaz WF, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized study versus haloperidol. CNS Spectr. 2009;14:93–102.

    PubMed  Google Scholar 

  32. Kobayashi H, Morita K, Takeshi K, et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol. 2009;5:421–5.

    Article  Google Scholar 

  33. Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week double-blind treatment with risperidone versus haloperidol. Int J Neuropsychopharmacol. 2009;9:1233–48.

    Article  Google Scholar 

  34. Kim SW, Shin JS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32:243–9.

    Article  PubMed  CAS  Google Scholar 

  35. Schooler N. Long-term treatment with asenapine versus olanzapine in subjects with predominant persistent negative symptoms of schizophrenia. 2009, Abstract SCR-26-076.

  36. Taylor D, Hanssens L, Loze JY, et al. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole versus standard of care, results from the STAR study. J Eur Psychiatry. 2008;23:336–43.

    Article  Google Scholar 

  37. Nasralla H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161:213–24.

    Article  Google Scholar 

  38. Rossi A, Vita A, Tiradritti P, et al. Assessment of clinical and metabolic status, and subjective well-being in schizophrenia patients switched from typical to atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;4:216–22.

    Article  Google Scholar 

  39. Ritsner M, Yorkov V, Ratner Y, et al. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia—a 12-month open-label, flexible-dose naturalistic observational study of patients undergoing usual care. Progr Neuro-Psycho Pharmacol Biol Psychiatry. 2007;31:1470–7.

    Article  CAS  Google Scholar 

  40. Arang C, Gomez-Beneyto M, Brenlla J, et al. A 6-month prospective observational, naturalistic uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Euro Neropsychopharmacol. 2007;17:456–63

    Google Scholar 

  41. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients—Schizophrenia Trial of aripiprazole: (STAR) study. Eur Psychiatry. 2007;7:433–43.

    Article  Google Scholar 

  42. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. AM J Psychiatry. 2007;164:428–36.

    Article  PubMed  Google Scholar 

  43. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment resistant schizophrenia: a double-blind comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213–23.

    Article  PubMed  CAS  Google Scholar 

  44. Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability and safety of aripiprazole in patients with schizophrenia or schizoaffective disorder: results of multicentre observational trial. Eur Psychiatry. 2007;22:195–202.

    Article  PubMed  Google Scholar 

  45. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia—an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:373–7.

    Article  PubMed  CAS  Google Scholar 

  46. Tandon R, Marcus RN, Stock EG, et al. A prospective multicentre randomized parallel-group open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness study trial with aripiprazole (BETA). Schizophr Res. 2006;84:77–89.

    Article  PubMed  Google Scholar 

  47. Rosenbeck RA, Leslie D, Sendelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080–9.

    Article  Google Scholar 

  48. Philips GA, Van Brunt DL, Roychowdhury SM, et al. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1397–403.

    Article  Google Scholar 

  49. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879–87.

    Article  PubMed  Google Scholar 

  50. Loebel A, Siu C, Romanos S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357–64.

    PubMed  Google Scholar 

  51. Voruganti LNP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berlin). 2004;171:121–32.

    Article  CAS  Google Scholar 

  52. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187–90.

    Article  PubMed  Google Scholar 

  53. Hogan TP, Awad AG, Eastwood MR. A self-report predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol Med. 1983;13:177–83.

    Article  PubMed  CAS  Google Scholar 

  54. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination of two measures. Psychol Med. 1992;22:347–52.

    Article  PubMed  CAS  Google Scholar 

  55. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr bull. 1993;19:609–18.

    Article  PubMed  CAS  Google Scholar 

  56. Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid abuse in schizophrenia and the emerging science of subjective tolerability. J Dual Design. 2005;1:83–95

    Google Scholar 

  57. Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmcoecon Outcomes Res. 2010;10:1–4.

    Article  Google Scholar 

  58. Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life and other clinical variables. Int J Clin Psychopharmacol. 1995; 10(suppl)30: 123–133.

    Google Scholar 

  59. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37–48.

    Article  PubMed  Google Scholar 

  60. Petall EA, Cooper H, Robinson C. The effects of choice on intrinsic motivation and related outcomes: a meta analysis of research findings. Psychol Bull. 2008;134:270–300.

    Article  Google Scholar 

  61. Rosenbeck R, Stroup S, Keefe RS, et al. Measuring outcome priorities and preferences in people with schizophrenia. Brit J Psychiatry. 1005;187:529–36.

    Article  Google Scholar 

  62. Awad AG. Antipsychotic medications: how satisfied are our patients? Clear Perspective, Management Issues in Schizophrenia 1999; 2: 1–6.

  63. Rofail D, Gray R, Gowrnay K, et al. The development and internal consistency of the satisfaction with antipsychotic scale. Psychol Med. 2005;35:1063–72.

    Article  PubMed  Google Scholar 

  64. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire. Psychopharmacol Bull. 1993;29:321–8.

    PubMed  CAS  Google Scholar 

  65. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118:271–8.

    Article  PubMed  Google Scholar 

  66. Brissos S, Molodynski A, Dias VV, et al. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry. 2011;10:1–7.

    Article  Google Scholar 

  67. Figueira M, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr Opin Psychiatry. 2001;24:91–9.

    Google Scholar 

  68. Heselgrave RJ, Awad AG, Voruganti LNP. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neuro Sci. 1997;22:235–43.

    Google Scholar 

  69. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008;21:630–9.

    Article  PubMed  Google Scholar 

  70. Bell M, Tsang HW, Greig TE, et al. Neurocognition, social cognition, perceived social discomfort and vocational outcomes in schizophrenia. Schizophr Bull. 2009;35:738–47.

    Article  PubMed  Google Scholar 

  71. Hugh D, Nuamah IF, Lim P, et al. Independent effect of paliperidone extended release on social functioning beyond its effects on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol. 2009;29:496–7.

    Article  Google Scholar 

  72. Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235–45.

    Article  PubMed  CAS  Google Scholar 

  73. Kawata T, Rivicki D. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17:1247–56.

    Article  PubMed  Google Scholar 

  74. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:585–8.

    Article  PubMed  CAS  Google Scholar 

  75. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2011;. doi:10-1007/s11136-011-0054-x.

    Google Scholar 

  76. Staniszewska S, Haywood K, Brett J, et al. Patient and public involvement in patient-reported outcome measures: evolution not revolution. Patient. 2012;5:79–87.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

No sources of funding were used to assist with the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review. The opinions expressed in this review are the authors’ own.

Author information

Authors and Affiliations

  1. Humber River Hospital, 2175 Keele Street, Room 243A, Toronto, ON, M6M 3Z4, Canada

    A. George Awad

  2. Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, Canada

    A. George Awad

  3. Department of Psychiatry, Oakville General Hospital, Oakville, ON, Canada

    Lakshmi N. P. Voruganti

Authors
  1. A. George Awad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lakshmi N. P. Voruganti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. George Awad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Awad, A.G., Voruganti, L.N.P. The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia. CNS Drugs 27, 625–636 (2013). https://doi.org/10.1007/s40263-013-0070-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-013-0070-1

Keywords

Search

Navigation